Chronic inflammation: the common thread linking lifestyle to cancer
Inflammation is everywhere in modern health conversation. It’s blamed for joint pain, skin conditions, cognitive fog, and much else besides. But when the focus is cancer, inflammation is not a lifestyle inconvenience — it’s a core mechanism linking nearly every other risk factor in this series to cancer development and progression.
When blood sugar is dysregulated, when sleep is disrupted, when stress hormones are chronically elevated, when diet is nutrient-poor, when exercise is absent — in each case, the body’s inflammatory signalling cascades outward. And sustained inflammatory signalling, orchestrated by molecules like TNF-α, IL-6, and NF-κB, creates an environment permissive to tumour initiation, promotion, and progression. This post pulls that thread together.
What chronic inflammation is, and why it matters for cancer
Inflammation is, fundamentally, a protective response. When you injure yourself or fight an infection, your immune system floods the area with inflammatory molecules — they recruit immune cells, increase blood flow, and trigger repair. That’s acute inflammation, and it’s essential.
Chronic inflammation is different. It’s a low-grade, persistent elevation in inflammatory signalling that persists even when no acute threat is present — sometimes called “metaflammation,” inflammation driven by metabolic dysfunction rather than infection or injury. It’s one of the most robust predictors of cancer risk in the epidemiological literature, and it operates through several distinct mechanisms.
Genomic instability. Chronic elevation of TNF-α and other inflammatory cytokines increases production of reactive oxygen species (ROS) inside cells. ROS damage DNA. In cells with impaired repair capacity, that damage accumulates — including in genes that govern cell cycle control. That’s a pathway toward malignant transformation.
Altered gene expression. NF-κB is a transcription factor that binds DNA and turns genes on and off. Chronic NF-κB activation — driven by elevated IL-6, TNF-α, and related signals — shifts cell behaviour toward survival and proliferation. It suppresses apoptosis (programmed cell death), one of the body’s primary brakes on cancer, and upregulates genes involved in angiogenesis, the blood vessel formation that growing tumours depend on.
Immune dysfunction. It might seem paradoxical, but chronic inflammation actually impairs immune surveillance — the process by which natural killer cells and cytotoxic T cells identify and destroy pre-cancerous cells. A perpetually inflamed immune system becomes skewed toward pro-tumour responses and away from effective anti-tumour immunity.
How we measure chronic inflammation, and what the evidence shows
The most commonly used clinical markers of systemic inflammation are C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α). All three are measurable in a standard blood test and all three have been studied in relation to cancer risk in large prospective cohort studies.
A 2012 meta-analysis published in International Journal of Cancer, synthesising 25 prospective cohort studies, found that individuals in the highest tertile of CRP had approximately a 30% increased risk of cancer overall, with particularly strong associations for colorectal cancer, liver cancer, and endometrial cancer. These were pre-diagnostic measurements — CRP elevated before any cancer diagnosis — which supports a causal rather than reactive interpretation.
A 2018 meta-analysis in Cytokine found that pre-diagnostic IL-6 levels predicted cancer incidence, with hazard ratios of 1.5–2.0 for the highest versus lowest quartiles. TNF-α shows similar patterns in prospective data. The consistency across markers and across cancer types points to inflammation as a genuine upstream driver, not simply a co-traveller.
Chronic inflammation as the common pathway
What’s striking about the chronic inflammation literature is how consistently it connects back to the lifestyle factors covered throughout this series.
Obesity and inflammation. Adipose tissue is an active endocrine organ that secretes IL-6 and TNF-α. People with excess visceral fat have higher circulating levels of both. As discussed in the post on obesity and breast cancer risk, this contributes directly to the inflammatory milieu that promotes oestrogen-sensitive cancers — and it’s not limited to breast cancer.
Poor diet quality and inflammation. Diets high in refined carbohydrates and ultra-processed foods drive postprandial blood sugar spikes, triggering acute inflammatory responses that, repeated across years, become chronic. These diets also alter the gut microbiome, reducing populations of beneficial bacteria that produce butyrate and other short-chain fatty acids with anti-inflammatory properties. A compromised gut barrier allows bacterial lipopolysaccharides (LPS) to enter the bloodstream, driving further systemic inflammation.
Physical inactivity and inflammation. Muscle is an endocrine organ that secretes anti-inflammatory molecules called myokines during contraction. People who exercise regularly have lower circulating TNF-α and IL-6. Sedentary people have higher levels. This is one of the most important mechanisms by which exercise reduces cancer risk — it acts as a biological anti-inflammatory.
Sleep disruption and inflammation. During deep sleep, inflammatory signalling is naturally dampened. Chronic sleep deprivation — whether from shift work, insomnia, or poor sleep hygiene — elevates circulating inflammatory markers. A 2020 study published in Brain, Behaviour, and Immunity found that people sleeping fewer than six hours per night had CRP levels approximately 40% higher than those sleeping seven to nine hours.
Chronic stress and inflammation. Sustained elevation of cortisol and other stress hormones drives inflammatory gene expression. Chronically stressed individuals show elevated CRP, IL-6, and TNF-α — one mechanism by which psychological stress translates into biological cancer risk, and one reason why stress reduction practices have measurable anti-inflammatory effects.
Alcohol and inflammation. Alcohol metabolism generates reactive oxygen species and directly stimulates inflammatory signalling in the liver and gut. This is one of several mechanisms by which alcohol carries carcinogenic risk, as covered in Post 6 of this series.
What this means in practice
The practical implication of inflammation as a common pathway is that reducing inflammation through lifestyle change is a central part of cancer prevention — and that each intervention in this series works, at least in part, through this mechanism.
The evidence does not yet show that lowering CRP, IL-6, or TNF-α directly prevents cancer — there are no RCTs testing this specifically. But the prospective data strongly suggest that the metabolic and immune improvements accompanying lifestyle change are protective, and inflammation reduction is a core part of that.
If inflammatory markers are measured as part of routine blood work (high-sensitivity CRP in particular), they can serve as a useful feedback signal. Elevated CRP is worth investigating: is sleep consistently short or fragmented? Is exercise absent? Is dietary quality poor? Is stress chronic and unmanaged? The answer usually points to at least one addressable factor.
Anti-inflammatory supplements — curcumin, omega-3 fatty acids, polyphenol extracts — are often promoted in this context. Some have reasonable evidence for lowering inflammatory markers in the short term, and the polyphenol and omega-3 data will be covered in later posts in this series. But they are not substitutes for the lifestyle foundations, and none has been shown to reduce cancer incidence in RCTs.
What the evidence does not yet show
There are no completed RCTs testing whether reducing inflammatory markers through lifestyle change reduces cancer incidence. This is partly because such trials would be enormous in scale, expensive, and require years of follow-up with careful measurement of both inflammation and cancer outcomes across a sufficient number of participants to detect meaningful differences.
The causal direction also warrants honesty. Whilst the prospective design of most cited studies — inflammatory markers measured before cancer diagnosis — supports a causal interpretation, it doesn’t eliminate the possibility that subclinical pre-cancerous processes drive inflammation before they are detectable as cancer. This is a genuine limitation of the observational literature.
It also bears repeating that anti-inflammatory supplements are not equivalent to anti-inflammatory lifestyle change. The body’s inflammatory machinery is complex, and single-compound interventions don’t replicate the systemic effects of consistent exercise, dietary quality, and adequate sleep.
The bottom line
Chronic inflammation is not a single risk factor — it’s the common biological language in which multiple risk factors speak. Obesity, poor diet, physical inactivity, sleep disruption, chronic stress, and excess alcohol all raise inflammatory signalling. And sustained inflammatory signalling creates the genomic instability, immune dysfunction, and permissive tissue environment in which cancer is more likely to develop.
Understanding inflammation as a unifying pathway doesn’t simplify cancer prevention to a single supplement or a single habit. It does clarify why the evidence-based strategies in this series — exercise, dietary quality, sleep, stress management — tend to work together rather than in isolation. They are all, in part, anti-inflammatory. And that convergence is meaningful.
Scientific references
- Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C-reactive protein and cancer. Journal of Epidemiology and Community Health. 2007;61(9):824–833. DOI: 10.1136/jech.2006.051292
- Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. International Journal of Cancer. 2011;128(12):2657–2663. DOI: 10.1002/ijc.26193
- Guo YZ, Pan L, Du CJ, et al. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pacific Journal of Cancer Prevention. 2013;14(1):243–248.
- Barrea L, Napolitano M, Balato N, et al. From the bench to the bedside: the role of interleukin-6 in the pathogenesis of psoriasis and cancer risk. Cytokine. 2018;111:260–267.
- Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biological Psychiatry. 2016;80(1):40–52. DOI: 10.1016/j.biopsych.2015.05.014
- Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature Reviews Endocrinology. 2012;8(8):457–465. DOI: 10.1038/nrendo.2012.49
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. DOI: 10.1016/j.cell.2011.02.013
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
